RET and neoplasm: Mutation in the TERT promoter hotspots C250T and C228T were the most frequent alterations found in 86/118 (73%) tumour specimens, followed by p53 alterations in 65/118 (55%), RAS (HRAS, KRAS and NRAS) in 23/118 (19.5%), CDKN2A mutations in 20/118 (16.9%), PI3KCA in 14/118 (11.8%), BRAF in 13/118 (11%) and RET in 9/118 (7.6%) of ATC.